Can-Fite Biopharma Ltd ADR Dossier - Source-backed chat

Can-Fite Biopharma Ltd ADR

CANFNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.31

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.21Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $4.7M

Enterprise Value −$793K

Shares Outstanding 1.6M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Can-Fite BioPharma Ltd. is an advanced clinical-stage biopharmaceutical company leveraging its proprietary A3 adenosine receptor (A3AR) platform technology to target multi-billion-dollar markets in oncology, liver, and inflammatory diseases. The company's lead candidates, Namodenoson and Piclidenoson, have demonstrated excellent safety profiles in over 1,600 patients and are currently advancing through pivotal Phase III trials. With regional licensing agreements already generating approximately $20 million in upfront and milestone payments, Can-Fite is well-positioned to secure broader global commercialization partnerships. Recent positive Phase 2a data in pancreatic cancer and the advancement of Namodenoson into a Phase 2b combination study with immunotherapy provide near-term clinical catalysts, while its cash runway is supported by recent warrant exercises and disciplined capital allocation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$8.00

Mean target$8.00

High · most bullish analyst$8.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects potential clinical trial delays, failure to meet primary endpoints in the Phase III HCC or psoriasis studies, or an inability to secure non-dilutive licensing revenue, forcing the company to rely heavily on dilutive equity financing or ATM facilities to sustain operations beyond its 12-month cash runway.

Base CaseCentral scenario

The base case assumes successful execution of the ongoing Phase III trials for Namodenoson in advanced HCC and Piclidenoson in psoriasis, with positive interim data in late 2026 leading to conditional regulatory filings. It also factors in the successful out-licensing of regional rights to major pharmaceutical markets, generating additional non-dilutive milestone payments and royalties.

Bull CaseUpside scenario

Successful Phase III readouts for Piclidenoson in psoriasis and Namodenoson in liver cancer, leading to FDA/EMA approvals and lucrative global commercialization partnerships.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Validated A3AR platform technology targeting highly expressed receptors in pathological cells while sparing normal cells, resulting in an excellent safety profile.
Two late-stage clinical assets (Namodenoson and Piclidenoson) in pivotal Phase III trials, significantly reducing early-stage development risks.
Established track record of regional out-licensing deals generating $20 million in upfront and milestone payments, demonstrating commercial viability.
Near-term clinical catalysts, including Vetbiolix canine osteoarthritis data in Q3 2026 and Namodenoson Phase III HCC interim analysis in late 2026.

Key Investment Risks

High dependency on clinical trial outcomes; negative or ambiguous data from pivotal Phase III trials would severely impact valuation.
Limited cash runway of approximately 12 months, requiring additional dilutive or non-dilutive financing to complete late-stage development.
Intense competition in the oncology, MASH, and psoriasis markets from established pharmaceutical companies with significantly greater resources.

Thesis Invalidation Triggers

Failure of Namodenoson to meet primary efficacy endpoints in the Phase III HCC interim analysis.
Inability to secure new strategic licensing partnerships or non-dilutive funding within the next 12 months.
Severe regulatory delays or safety holds imposed by the FDA or EMA on ongoing clinical programs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.